

**Mapping of reporting guidance for systematic reviews and meta-analyses generated a comprehensive item bank for future reporting guidelines**

Page, Matthew J; McKenzie, Joanne E; Bossuyt, Patrick M; Boutron, Isabelle; Hoffmann, Tammy; Mulrow, Cynthia D; Shamseer, Larissa; Moher, David

*Published in:*  
Journal of Clinical Epidemiology

*DOI:*  
[10.1016/j.jclinepi.2019.11.010](https://doi.org/10.1016/j.jclinepi.2019.11.010)

*Licence:*  
CC BY-NC-ND

[Link to output in Bond University research repository.](#)

*Recommended citation(APA):*  
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T., Mulrow, C. D., Shamseer, L., & Moher, D. (2020). Mapping of reporting guidance for systematic reviews and meta-analyses generated a comprehensive item bank for future reporting guidelines. *Journal of Clinical Epidemiology*, 118, 60-68.  
<https://doi.org/10.1016/j.jclinepi.2019.11.010>

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator.

This is not the final published version. Final version can be found at:

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann T, Mulrow CD, Shamseer L, Moher D. Mapping of reporting guidance for systematic reviews and meta-analyses generated a comprehensive item bank for future reporting guidelines. *Journal of Clinical Epidemiology* 2019. DOI: <https://doi.org/10.1016/j.jclinepi.2019.11.010>

© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>

## Mapping of reporting guidance for systematic reviews and meta-analyses generated a comprehensive item bank for future reporting guidelines

Matthew J Page<sup>1</sup>, Joanne E McKenzie<sup>1</sup>, Patrick M Bossuyt<sup>2</sup>, Isabelle Boutron<sup>3,4,5</sup>, Tammy Hoffmann<sup>6</sup>, Cynthia D Mulrow<sup>7</sup>, Larissa Shamseer<sup>8</sup>, David Moher<sup>8,9</sup>

1. School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
2. Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, Netherlands
3. Université de Paris, CRESS, INSERM, INRA, F-75004 Paris, France
4. Faculté de Médecine, Paris Descartes University, Paris, France
5. Centre d'Épidémiologie Clinique, AP-HP (Assistance Publique des Hôpitaux de Paris), Hôpital Hôtel Dieu, Paris, France
6. Institute for Evidence-Based Healthcare, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland, Australia
7. University of Texas Health Science Center at San Antonio, San Antonio, TX, United States
8. School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada
9. Centre for Journalology and Canadian EQUATOR Centre, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada

**Correspondence to:** Dr. Matthew Page, School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Road, Melbourne, Victoria, 3004, Australia. Telephone: +61 9903 0248. Email address: [matthew.page@monash.edu](mailto:matthew.page@monash.edu)

**Keywords:** Reporting; Systematic Reviews; Methodology; Quality

**Word count:** 3,623 (main text), 2 figures, 1 appendix

## **Abstract**

**Objectives:** To generate a comprehensive bank of systematic review (SR) reporting items to inform an update of the PRISMA 2009 statement.

**Methods:** We searched the EQUATOR Network library in May 2019 to identify all reporting guidelines for SRs that were published after 2009, regardless of the scope of the guideline. We also conducted a selective review of four guidance manuals for SRs, three tools for assessing risk of bias in SRs, six meta-research studies evaluating the reporting quality of SRs using a tailored checklist, and five reporting guidelines for other study designs. One author screened and selected sources for inclusion, extracted reporting guidance from sources, and mapped guidance against the PRISMA 2009 checklist items.

**Results:** We included 60 sources providing guidance on reporting of SRs and meta-analyses. From these, we collated a list of 221 unique reporting items. Items were categorised into title (four items), abstract (10 items), introduction (12 items), methods (111 items), results (61 items), discussion (12 items), funding and conflicts of interest (4 items), administrative information (3 items), and data availability (4 items). This exercise generated 175 reporting items that could be added to the guidance in the PRISMA 2009 statement.

**Conclusions:** Generation of a comprehensive item bank through review and mapping of the literature facilitates identification of missing items, and those needing modification, which may not otherwise be identified by the guideline development team or from other activities commonly used to develop reporting guidelines.

## 1. Background

The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement is a reporting guideline designed to help authors prepare a transparent and reproducible account of a systematic review (SR) (1, 2). It focuses primarily on SRs and meta-analyses of studies that evaluate healthcare interventions but can also be used as a basis for reporting SRs of other types of research. The PRISMA statement was published simultaneously in 2009 in multiple medical journals (*Annals of Internal Medicine* (3), *BMJ* (4), *Journal of Clinical Epidemiology* (5), and *PLoS Medicine* (1)). An 'explanation and elaboration' paper was also published concurrently in these four journals (2, 6-8), providing detailed guidance for each item along with examples of exemplary reporting found in the literature. The PRISMA statement has been adopted widely by authors and journals, as evidenced through citations (more than 30,000 times (Scopus, June 2019)) and endorsement by more than 400 journals.

There have been many methodological developments affecting SR conduct and reporting in the 10 years since PRISMA was published. These developments include novel guidance on how to identify studies for inclusion (9-11), synthesise and present findings when meta-analysis is not possible or appropriate (12, 13), report and synthesise intervention characteristics of included studies (14, 15), and enhance the reproducibility of meta-analytic results (16, 17). There have also been improvements in the understanding of sources of bias and methodological quality in SRs, culminating in the development of the Risk Of Bias In Systematic reviews (ROBIS) (18) and AMSTAR-2 (19) tools. In December 2017, we initiated a project to update the PRISMA statement to incorporate new items and guidance arising from these and other methodological developments.

In the EQUATOR (Enhancing the QUALity and Transparency Of health Research) Network's guidance for developers and updaters of health research reporting guidelines, Moher et al. recommend that initial steps should include (a) seeking evidence on the quality of reporting in published research articles and (b) identifying previous relevant reporting guidance for such studies (20). Page et al. recently addressed step (a) in this process, by conducting several evaluations of the reporting quality of published SRs (21-24). However, there has been no attempt to comprehensively identify items from other reporting guidance for SRs and map these against items recommended in the PRISMA 2009 statement. Doing so could help reveal what (if any) items are currently missing from the PRISMA 2009 statement, and provide a useful item bank for those seeking to generate reporting guidelines for types of SRs and meta-analyses that fall outside the scope of PRISMA 2009 (e.g. SRs in disciplines other than health), or those wishing to update existing reporting guidelines for SRs. The aim of this study therefore was to generate a comprehensive bank of SR reporting items to inform an update of the PRISMA 2009 statement.

## 2. Methods

We registered the PRISMA update with the EQUATOR Network website in December 2017 (<http://www.equator-network.org/library/reporting-guidelines-under-development/#86>), and our study protocol was registered with the Open Science Framework in February 2018 (25).

### 2.1. Search and selection of articles

We performed several tasks to identify reporting guidance for SRs. On March 1, 2018, one author (MJP) screened the titles of all 398 reporting guidelines listed in the publicly available library maintained by the EQUATOR Network (<http://www.equator-network.org/reporting-guidelines/>). The library was checked again on 31 May 2019; by that time, 413 guidelines were available. From this list we included all PRISMA extensions and other reporting guidelines for SRs and other evidence syntheses published after 2009 (when PRISMA was published), regardless of the scope of the guideline (e.g. any discipline or type of included studies). The same author also sought reporting guidance that was available in four manuals for SRs of healthcare interventions (the 2011 Cochrane

Handbook for Systematic Reviews of Interventions (26), the 2011 US Institute of Medicine's Standards for Systematic Reviews (27), the 2014 US Agency for Healthcare Research and Quality (AHRQ) Methods Guide for Effectiveness and Comparative Effectiveness Reviews (28) and the 2017 Joanna Briggs Institute Reviewers Manual (29)).

The same author also reviewed items included in three recently developed critical appraisal tools for assessing risk of bias or methodological quality in SRs (the tool to assess the quality of a meta-analysis developed by Higgins et al. (30), the ROBIS tool (18), and AMSTAR-2 (19)). Six meta-research studies (21, 23, 24, 31-33) in the lead author's personal collection which included an evaluation of the reporting quality of SRs using a tailored reporting checklist were also reviewed. Five key reporting guidelines for other study designs published after 2009 (e.g. CONSORT 2010 (34), SPIRIT 2013 (35), STARD 2015 (36), the 2015 TOP guidelines (37) and the 2017 guidelines for the content of statistical analysis plans in clinical trials (38)) were reviewed to identify general items that could potentially be added to the PRISMA statement, and to improve consistency of wording and style with other reporting guidelines. The list of sources identified was sent to all co-authors, who were invited to suggest additional sources to review.

We also conducted a systematic search for published comments on, or suggested revisions to, the PRISMA 2009 statement. One author (MJP) searched for potentially relevant articles indexed in MEDLINE® (specifically, Ovid MEDLINE® Epub Ahead of Print, In-Process & Other Non-Indexed Citations; Ovid MEDLINE® Daily; and Ovid MEDLINE and Versions®) from inception to 31 July 2017 (the same search was used to identify studies evaluating the reporting quality of published SRs, as summarised by Page and Moher (22)). The following search strategy was used to retrieve articles that included the term "PRISMA" (abbreviated or spelled out in full) in the title or abstract of the article:

1. "Preferred Reporting Items for Systematic reviews and Meta-analyses".ti,ab.
2. PRISMA.ti,ab.
3. 1 or 2.

One author (MJP) screened all titles and abstracts yielded from the searches, and any full text articles considered potentially relevant.

## **2.2. Compiling of reporting items**

From all the included sources, one author (MJP) extracted all guidance that they deemed potentially relevant to the reporting of SRs and meta-analyses of interventions. Guidance for *conduct* of SRs and meta-analyses (e.g. "Search appropriate national, regional and subject-specific bibliographic databases" (39)) was not extracted. Reporting guidelines for SRs were reviewed in chronological order (from oldest to newest), starting with the PRISMA 2009 statement, followed by each of its extensions, and then other sources (the order in which sources were reviewed is shown in Table S1 in the Appendix). Reporting guidance was extracted verbatim from both the checklist and 'explanation and elaboration' paper (where available) for each included reporting guideline.

Reporting items were extracted into a table created in Microsoft Word, with one column for the reporting item and another for the source of the text extracted; each row in the table represented a single reporting item. The table was populated initially with each of the PRISMA 2009 checklist items and any corresponding reporting guidance found in the PRISMA 2009 'explanation and elaboration' paper. This resulted in an initial list of 46 reporting items (19 of the 27 PRISMA 2009 checklist items had additional reporting guidance in the 'explanation and elaboration' paper whereas the following eight items did not: 2, 4, 15, 18, 19, 24, 25 and 26). The table was then populated by recording from other sources all relevant reporting guidance that differed in any way from what was previously extracted. For example, item 5 of the PRISMA 2009 checklist recommends that authors "Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide

registration information including registration number” (1). The corresponding item in the PRISMA extension for diagnostic test accuracy (DTA) studies recommends that authors “Indicate *where the review protocol can be accessed* (e.g., Web address) *and provide registration number if available*” (40) (emphasis added). Both items were extracted in this instance given that the wording is slightly different.

We did not extract items that apply only to specific types or aspects of SRs (e.g. items relevant only to DTA SRs, or child-relevant SRs). Once all PRISMA extensions were reviewed, all reporting guidelines for SRs produced by other organisations/authors, other guidance documents (e.g. SR handbooks), critical appraisal tools and other included articles were reviewed in a similar way to identify additional reporting items not captured from PRISMA 2009 or its extensions. The iterative process used meant that each time a new source was reviewed, items already extracted were revisited to determine whether the new source contained unique reporting guidance. After reviewing all sources, each source was reviewed a second time in the same order by the sole data extractor (MJP) to minimise the chance of missing relevant items.

Once all sources had been reviewed twice, one author (MJP) read the reporting guidance extracted from all sources and compiled a list of unique reporting items. This was done by comparing and contrasting the text extracted and removing any guidance deemed redundant (i.e. covering the same conceptual or methodological issue). The final list of unique items was structured by presenting each PRISMA 2009 checklist item (1) and corresponding guidance from the ‘explanation and elaboration’ paper (2), followed by any additional reporting guidance relevant to that item not included in these two sources. For some of the items presented in the list of unique reporting items, we changed the wording from the original source to make it more applicable to SRs of interventions, or broke a comprehensive item into multiple sub-items to facilitate clarity.

We counted the number of unique reporting items across all included sources and the number of items not currently included in the 27 sections of the PRISMA 2009 checklist and ‘explanation and elaboration’ paper that could potentially be added in the update of the guideline.

### **2.3. Deviations from the protocol**


We planned to conduct a formal systematic search for methodological studies (or SRs thereof) that provide guidance on how to conduct or report SRs and meta-analyses (25). We intended to do this by searching MEDLINE® and Embase, adapting the search strategy used by McGrath et al. to identify literature to inform the development of the PRISMA-DTA extension (41). However, formal searching in March 2018 proved difficult and resulted in a very large number of records (>46,000) to screen, very few of which we assumed would be relevant. Therefore, we did not carry out this planned step in our process.

### **3. Results**

We reviewed 60 sources (presented in 56 reports) that provided reporting guidance for SRs and meta-analyses (1, 2, 14, 15, 17-19, 21, 23, 24, 26-38, 40-72) (included reports are listed in Table S1 in the Appendix, also available at <https://osf.io/kbj6v/>). Half (n=30) of the sources were published in 2016 or later. Included sources were: the PRISMA 2009 statement and all of its published extensions (both the checklist and ‘explanation and elaboration’ for each were reviewed), 26 other sources providing reporting guidance for SRs (including other reporting guidelines and SR manuals), three tools for assessing risk of bias or methodological quality in SRs, six studies that evaluated the reporting quality of SRs using a tailored reporting checklist, and five reporting guidelines for other study designs.

The search of MEDLINE® for published comments on, or suggested revisions to, the PRISMA 2009 statement, yielded 5,001 citations. After screening each title and abstract, the full text of 170 articles was retrieved, and 43 met the inclusion criteria (listed in Table S2 in the Appendix, also available at <https://osf.io/kbj6v/>). However, none of the 43 articles contained any additional relevant reporting items which had not already been identified from the 60 sources described above, so are not discussed further.

A total of 349 reporting items were extracted from the 60 sources (Figure 1). After comparing and contrasting the items to check for redundancy, we compiled a list of 221 unique reporting items deemed relevant to SRs and meta-analyses of interventions (Table S3 in the Appendix, also available at <https://osf.io/kbj6v/>; the complete list of 349 items extracted verbatim from each source is presented in Table S4 in the Appendix, also available at <https://osf.io/kbj6v/>). We categorised the 221 unique reporting items into the following broad categories: title (four items), abstract (10 items), introduction (12 items), methods (111 items), results (61 items), discussion (12 items), funding and conflicts of interest (four items), administrative information (three items), and data availability (four items).




**Figure 1. Flow diagram of extraction and compilation of reporting items. “E&E” = explanation and elaboration paper.**

There was at least one new relevant reporting item that could be added to the 46 items extracted from the 27 sections of the PRISMA 2009 checklist and ‘explanation and elaboration’ paper (1, 2). In total, 175 additional items were compiled (168 items were relevant to the 27 sections of PRISMA 2009 (Figure 2) and seven items were not captured by PRISMA 2009). The sections of PRISMA 2009 with the highest number of additional items compiled were:

- methods for synthesizing results (18 additional items, for example, more detail about the statistical methods for meta-analysis used, descriptions of synthesis or summary methods used when meta-analysis was not possible or appropriate);
- results of the synthesis (14 additional items, for example, more detail about what information to report for each result, such as an effect estimate, confidence interval, prediction interval (when appropriate) and a description of the direction of the effect);
- study characteristics (13 additional items, for example, a comprehensive summary of the intervention details for each study, conflicts of interest of study authors, and sources of funding for each study);

- information sources (12 additional items, for example, more detail about the particular reference lists examined, journals hand searched, and researchers contacted to identify studies, and whether any update to searches was undertaken during the conduct of the review); and
- data items collected (12 additional items, for example, defining in detail all outcomes and data collection of potential effect modifiers).

The seven additional items that do not map to the PRISMA 2009 statement address administrative information (e.g. affiliations and contributions of authors) and data availability (e.g. making data sets and statistical analysis code available).



**Figure 2. Number of additional items relevant to the 27 sections of the PRISMA 2009 statement that were compiled from other sources but not included in the PRISMA 2009 checklist or ‘explanation and elaboration’ paper (see Table S3 in the Appendix for complete list of items)**

In the 60 sources from which we collated reporting items, four included a proposal for an alternative PRISMA flow diagram of the identification, screening and inclusion of studies (60, 67, 69, 72). Proposals included: the addition of a text box indicating the number of studies included in a previous version of the review (for SR updates) (60); separate flow diagrams for different information sources (e.g. one for bibliographic databases, another for trials registers) (69); modifications to the formatting within and layout of text boxes (67); and the addition of text boxes indicating the number of irretrievable full texts, pre-screened articles from other sources, and studies not included in the synthesis, with reasons (72).

#### **4. Discussion**

Based on a selective search for existing guidance on the reporting of SRs and meta-analyses, we compiled a list of 221 reporting items of potential relevance to SRs and meta-analyses of interventions. Most of the items (n=111) apply to the methods section of a SR, with information about the information sources consulted, data items collected, and methods for synthesizing results used being the most common. This review generated 175 reporting items that could potentially be added in an update of the guidance in the PRISMA 2009 statement, including modifications to existing items and addition of new items.

A major strength of this research is the inclusion of multiple sources of guidance for SRs and meta-analyses, regardless of the discipline from which they originated (e.g. medicine, psychology, or environmental research) or the type of synthesis to which the guidance applies (e.g. SRs of intervention studies or SRs of DTA studies). Doing so resulted in an extensive set of potential reporting items for consideration. As the majority of sources were published from 2015 onwards, they should provide guidance that is relevant to current SRs.

Our findings should be interpreted in light of some limitations. We did not seek the rationale for or evidence underpinning each item extracted (as described by the authors/guideline developers). Therefore, readers should consider the current list of reporting items in Table S3 in the Appendix as possible contenders for inclusion in the updated PRISMA statement, since items have not been ranked in terms of priority for reporting. Also, the selection of sources, extraction of items from sources, and compiling of items was performed by one author only, so it is possible that additional sources and items would have been identified had another author undertaken this exercise. However, the author reviewed each source twice, which likely minimised the chance of missing relevant items.

To our knowledge, this is the first attempt to map the content of other reporting guidance for SRs and meta-analyses against items recommended in the PRISMA 2009 statement. The most similar exercise that we are aware of was that conducted by McGrath et al. in preparation for the PRISMA-DTA extension (41). The authors systematically searched methodological literature on SRs of diagnostic test accuracy and identified 19 unique sources from which they compiled a list of 64 reporting items. All the items identified by McGrath et al. that are relevant to SRs of interventions were identified in our search also. That more sources (n=60) and items (n=221) were identified in our study likely reflects the greater attention that SR methodologists have devoted to SRs of interventions.

The large number of reporting items not captured in PRISMA 2009 that this exercise generated illustrates the value of systematically mapping reporting guidance in previous reporting guidelines, handbooks and critical appraisal tools when developing or updating any reporting guideline. Generation of a comprehensive item bank through review and mapping of the literature facilitates identification of missing items, and those needing modification, which may not otherwise be identified by the guideline development team or from other activities commonly used to develop

reporting guidelines (e.g. Delphi exercise). Use of the item bank to frame discussion at guideline consensus meetings can also potentially help to mitigate the groupthink that can occur in such meetings. We encourage reporting guideline developers to start a review of reporting guidance by searching the publicly available library maintained by the EQUATOR Network, along with other key sources providing reporting guidance for the study design of interest. Developers should consider including in the review tools designed to appraise the reporting quality of published studies. Doing so can help ensure that what is recommended for reporting in the reporting guideline aligns with what is expected to have been reported by developers of the critical appraisal tool (73). Developers should also document the findings of the literature review transparently so that users can understand clearly what materials and content informed the final reporting guideline developed.

Despite evidence of improved reporting of SRs over time (21), an increasing body of literature suggests that adherence to PRISMA 2009 is suboptimal (22). In a synthesis of 23 studies evaluating the reporting quality of 2,382 SRs published after the PRISMA statement was disseminated, nine of the 27 PRISMA items were adhered to by fewer than two-thirds of the SRs (22). Poorly reported items included SR registration details or existence of a SR protocol, a full electronic search strategy, methods for assessing risk of bias in individual studies, and funding source for the SR. The item bank generated in this study was developed to ensure we started with a comprehensive list of items to consider for inclusion in the updated PRISMA statement, not to address the issue of poor adherence to PRISMA. There is a risk that expanding PRISMA to include *all* items identified in our item bank will prove a greater barrier to adherence to PRISMA in the future, given the extra burden on authors. Therefore, additional work is needed to select items from the item bank that represent an optimal minimum set for authors reporting SRs and meta-analyses, which is informed by evidence that supports their reporting, expert consensus and user testing.

The items identified in this review subsequently formed the basis of a survey of systematic reviewers, methodologists and journal editors (conducted in July 2018, results forthcoming). Participants were invited to comment on each of the existing 27 items in the PRISMA 2009 checklist, indicating whether they preferred to maintain the item, modify the item, or remove the item from the checklist. Participants were also asked whether each potential new item proposed should be included in the updated statement, and if so, whether it should be included in the checklist or 'explanation and elaboration' paper. Additionally, survey respondents were given the opportunity to propose additional items throughout the survey. We discussed the findings of the survey at an in-person consensus meeting in September 2018. Development of the updated PRISMA statement (informed by the literature review, survey and meeting discussions) is ongoing. Once the statement has been updated, we also plan to use various strategies to increase adherence that have been used successfully when implementing other reporting guidelines (74).

## **5. Conclusion**

We encourage others wishing to generate reporting guidelines for types of SRs and meta-analyses that fall outside the scope of PRISMA 2009 (e.g. SRs in disciplines other than health), or those wishing to update existing reporting guidelines for SRs, to make use of the item bank collated in this study. Doing so should reduce redundancy of effort and ensure that guideline developers start with a comprehensive list of items to consider for inclusion. We found this to be a valuable first step in the update of the PRISMA statement for SRs and meta-analyses and advise developers of reporting guidelines for other study designs to consider adopting a comparable, rigorous approach to item generation.

**Declarations****Competing Interests**

MJP and DM are Editorial Board members for the *Journal* but had no involvement in the peer review process or decision to publish. No other authors have any competing interests in relation to the submitted work.

**Funding**

MJP was supported by an Australian National Health and Medical Research Council (NHMRC) Early Career Fellowship (1088535) during the conduct of this research. JEM is supported by an Australian NHMRC Career Development Fellowship (1143429). TH is supported by an Australian NHMRC Senior Research Fellowship (1154607). DM is supported in part by a University Research Chair, University of Ottawa. The funders had no role in the study design, data collection and analysis, or preparation of the manuscript.

**Author Contributions**

All authors declare to meet the ICMJE conditions for authorship. MJP and DM conceived the study design. All authors provided input into the study design and suggested sources for inclusion in the review. MJP collected data and classified reporting items. MJP wrote the first draft of the article. All authors contributed to revisions of the article. All authors approved the final version of the submitted article.

**Data Availability**

All data are available within the paper and on the Open Science Framework at <https://osf.io/kbj6v/>.

## References

1. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 2009;6(7):e1000097.
2. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med.* 2009;6(7):e1000100.
3. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med.* 2009;151(4):264-9, W64.
4. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ.* 2009;339:b2535.
5. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol.* 2009;62(10):1006-12.
6. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol.* 2009;62(10):e1-34.
7. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ.* 2009;339:b2700.
8. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med.* 2009;151(4):W65-94.
9. O'Mara-Eves A, Thomas J, McNaught J, Miwa M, Ananiadou S. Using text mining for study identification in systematic reviews: a systematic review of current approaches. *Systematic Reviews.* 2015;4:5.
10. Shemilt I, Khan N, Park S, Thomas J. Use of cost-effectiveness analysis to compare the efficiency of study identification methods in systematic reviews. *Systematic Reviews.* 2016;5(1):140.
11. Mortensen ML, Adam GP, Trikalinos TA, Kraska T, Wallace BC. An exploration of crowdsourcing citation screening for systematic reviews. *Research Synthesis Methods.* 2017;8(3):366-86.
12. Higgins JPT, Lopez-Lopez JA, Becker BJ, Davies SR, Dawson S, Grimshaw JM, et al. Synthesising quantitative evidence in systematic reviews of complex health interventions. *BMJ Global Health.* 2019;4(Suppl 1):e000858.
13. McKenzie JE, Brennan SE. Chapter 12: Synthesizing and presenting findings using other methods. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. *Cochrane Handbook for Systematic Reviews of Interventions.* 2nd ed. Chichester (UK): John Wiley & Sons; 2019.
14. Hoffmann TC, Oxman AD, Ioannidis JP, Moher D, Lasserson TJ, Tovey DI, et al. Enhancing the usability of systematic reviews by improving the consideration and description of interventions. *BMJ.* 2017;358:j2998.
15. Glasziou PP, Chalmers I, Green S, Michie S. Intervention synthesis: a missing link between a systematic review and practical treatment(s). *PLoS Med.* 2014;11(8):e1001690.
16. Li T, Vedula SS, Hadar N, Parkin C, Lau J, Dickersin K. Innovations in data collection, management, and archiving for systematic reviews. *Ann Intern Med.* 2015;162(4):287-94.
17. Lakens D, Hilgard J, Staaks J. On the reproducibility of meta-analyses: six practical recommendations. *BMC Psychol.* 2016;4(1):24.
18. Whiting P, Savovic J, Higgins JP, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. *J Clin Epidemiol.* 2016;69:225-34.

19. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ*. 2017;358:j4008.
20. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. *PLoS Med*. 2010;7(2):e1000217.
21. Page MJ, Shamseer L, Altman DG, Tetzlaff J, Sampson M, Tricco AC, et al. Epidemiology and Reporting Characteristics of Systematic Reviews of Biomedical Research: A Cross-Sectional Study. *PLoS Med*. 2016;13(5):e1002028.
22. Page MJ, Moher D. Evaluations of the uptake and impact of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement and extensions: a scoping review. *Systematic Reviews*. 2017;6(1):263.
23. Page MJ, Altman DG, Shamseer L, McKenzie JE, Ahmadzai N, Wolfe D, et al. Reproducible research practices are underused in systematic reviews of biomedical interventions. *J Clin Epidemiol*. 2018;94:8-18.
24. Page MJ, Altman DG, McKenzie JE, Shamseer L, Ahmadzai N, Wolfe D, et al. Flaws in the application and interpretation of statistical analyses in systematic reviews of therapeutic interventions were common: a cross-sectional analysis. *J Clin Epidemiol*. 2018;95:7-18.
25. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann T, Mulrow CM, et al. Updating the PRISMA reporting guideline for systematic reviews and meta-analyses. Retrieved from [osf.io/2v7mk](https://osf.io/2v7mk). 2018, February 14.
26. Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]*. The Cochrane Collaboration, 2011. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org).
27. IOM (Institute of Medicine). *Finding What Works in Health Care: Standards for Systematic Reviews*. Washington, DC: The National Academies Press; 2011.
28. *Methods Guide for Effectiveness and Comparative Effectiveness Reviews*. AHRQ Publication No. 10(14)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. January 2014. Chapters available at: [www.effectivehealthcare.ahrq.gov](http://www.effectivehealthcare.ahrq.gov).
29. Aromataris E, Munn Z. *Joanna Briggs Institute Reviewer's Manual*. The Joanna Briggs Institute, 2017. Available from <https://reviewersmanual.joannabriggs.org/>
30. Higgins JP, Lane PW, Anagnostelis B, Anzures-Cabrera J, Baker NF, Cappelleri JC, et al. A tool to assess the quality of a meta-analysis. *Research Synthesis Methods*. 2013;4(4):351-66.
31. Ioannidis JP. The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses. *Milbank Q*. 2016;94(3):485-514.
32. Hammad TA, Nayarapally GA, Pinheiro SP, Iyasu S, Rochester G, Dal Pan G. Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: an empirical assessment. *Clinical Trials*. 2013;10(3):389-97.
33. Riaz IB, Khan MS, Riaz H, Goldberg RJ. Disorganized Systematic Reviews and Meta-analyses: Time to Systematize the Conduct and Publication of These Study Overviews? *Am J Med*. 2016;129(3):339.e11-8.
34. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340:c332.
35. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med*. 2013;158(3):200-7.
36. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. *BMJ*. 2015;351:h5527.
37. Nosek BA, Alter G, Banks GC, Borsboom D, Bowman SD, Breckler SJ, et al. SCIENTIFIC STANDARDS. Promoting an open research culture. *Science*. 2015;348(6242):1422-5.

38. Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Dore C, et al. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. *JAMA*. 2017;318(23):2337-43.
39. Higgins JPT, Lasserson T, Chandler J, Tovey D, Churchill R. *Methodological Expectations of Cochrane Intervention Reviews (v1.04)*. London: Cochrane; 2017.
40. McInnes MF, Moher D, Thombbs BD, McGrath TA, Bossuyt PM, and the PRISMA-DTA Group. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: The PRISMA-DTA statement. *JAMA*. 2018;319(4):388-96.
41. McGrath TA, Alabousi M, Skidmore B, Korevaar DA, Bossuyt PM, Moher D, et al. Recommendations for reporting of systematic reviews and meta-analyses of diagnostic test accuracy: a systematic review. *Systematic Reviews*. 2017;6(1):194.
42. Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, et al. PRISMA-Equity 2012 extension: reporting guidelines for systematic reviews with a focus on health equity. *PLoS Med*. 2012;9(10):e1001333.
43. Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, et al. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration. *International Journal for Equity in Health*. 2015;14:92.
44. Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H, Chalmers I, et al. PRISMA for Abstracts: Reporting Systematic Reviews in Journal and Conference Abstracts. *PLoS Med*. 2013;10:e1001419.
45. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med*. 2015;162(11):777-84.
46. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. *JAMA*. 2015;313(16):1657-65.
47. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews*. 2015;4:1.
48. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*. 2015;349:g7647.
49. Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. *BMJ*. 2016;352:i157.
50. Farid-Kapadia M, Joachim KC, Balasingham C, Clyburne-Sherin A, Offringa M. Are child-centric aspects in newborn and child health systematic review and meta-analysis protocols and reports adequately reported?-two systematic reviews. *Systematic Reviews*. 2017;6(1):31.
51. Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P, et al. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. *J Clin Epidemiol*. 2017;90:43-50.
52. Guise JM, Butler M, Chang C, Viswanathan M, Pigott T, Tugwell P, et al. AHRQ series on complex intervention systematic reviews-paper 7: PRISMA-CI elaboration and explanation. *J Clin Epidemiol*. 2017;90:51-8.
53. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-SCR): Checklist and explanation. *Ann Intern Med*. 2018;169(7):467-73.
54. Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ. *BMC Medical Research Methodology*. 2012;12:181.

55. Kable AK, Pich J, Maslin-Prothero SE. A structured approach to documenting a search strategy for publication: a 12 step guideline for authors. *Nurse Educ Today*. 2012;32(8):878-86.
56. Wong G, Greenhalgh T, Westhorp G, Buckingham J, Pawson R. RAMESES publication standards: realist syntheses. *BMC Medicine*. 2013;11:21.
57. Wong G, Greenhalgh T, Westhorp G, Buckingham J, Pawson R. RAMESES publication standards: meta-narrative reviews. *BMC Medicine*. 2013;11:20.
58. Gagnier JJ, Morgenstern H, Altman DG, Berlin J, Chang S, McCulloch P, et al. Consensus-based recommendations for investigating clinical heterogeneity in systematic reviews. *BMC Medical Research Methodology*. 2013;13:106.
59. Montgomery P, Underhill K, Gardner F, Operario D, Mayo-Wilson E. The Oxford Implementation Index: a new tool for incorporating implementation data into systematic reviews and meta-analyses. *J Clin Epidemiol*. 2013;66(8):874-82.
60. Stovold E, Beecher D, Foxlee R, Noel-Storr A. Study flow diagrams in Cochrane systematic review updates: an adapted PRISMA flow diagram. *Systematic Reviews*. 2014;3:54.
61. Atkinson KM, Koenka AC, Sanchez CE, Moshontz H, Cooper H. Reporting standards for literature searches and report inclusion criteria: making research syntheses more transparent and easy to replicate. *Research Synthesis Methods*. 2015;6(1):87-95.
62. Vries RBM, Hooijmans CR, Langendam MW, Luijk J, Leenaars M, Ritskes-Hoitinga M, et al. A protocol format for the preparation, registration and publication of systematic reviews of animal intervention studies. *Evidence-based Preclinical Medicine*. 2015;2(1):e00007.
63. Paynter R, Banez LL, Berliner E, Erinoff E, Lege-Matsuura J, Potter S, et al. AHRQ Methods for Effective Health Care. EPC Methods: An Exploration of the Use of Text-Mining Software in Systematic Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016.
64. Churchill R, Lasserson T, Chandler J, Tovey D, Higgins JPT. Standards for the reporting of new Cochrane Intervention Reviews. In: Higgins JPT, Lasserson T, Chandler J, Tovey D, Churchill R, editors. *Methodological Expectations of Cochrane Intervention Reviews (v1.04)*. London: Cochrane; 2017.
65. Chandler J, Lasserson T, Higgins JPT, Tovey D, Churchill R. Standards for the planning, conduct and reporting of updates of Cochrane Intervention Reviews. In: Higgins JPT, Lasserson T, Chandler J, Tovey D, Churchill R, editors. *Methodological Expectations of Cochrane Intervention Reviews (v1.04)*. London: Cochrane; 2017.
66. The Methods Group of the Campbell Collaboration. Methodological expectations of Campbell Collaboration intervention reviews: Reporting standards. Last updated 6 December 2017. *Campbell Policies and Guidelines Series No. 4*. DOI: 10.4073/cpg.2016.4.
67. Boers M. Graphics and statistics for cardiology: designing effective tables for presentation and publication. *Heart*. 2018;104(3):192-200.
68. Muller VI, Cieslik EC, Laird AR, Fox PT, Radua J, Mataix-Cols D, et al. Ten simple rules for neuroimaging meta-analysis. *Neurosci Biobehav Rev*. 2018;84:151-61.
69. Mayo-Wilson E, Li T, Fusco N, Dickersin K. Practical guidance for using multiple data sources in systematic reviews and meta-analyses (with examples from the MUDS study). *Research Synthesis Methods*. 2018;9(1):2-12.
70. Appelbaum M, Cooper H, Kline RB, Mayo-Wilson E, Nezu AM, Rao SM. Journal article reporting standards for quantitative research in psychology: The APA Publications and Communications Board task force report. *Am Psychol*. 2018;73(1):3-25.
71. Levitt HM, Bamberg M, Creswell JW, Frost DM, Josselson R, Suarez-Orozco C. Journal article reporting standards for qualitative primary, qualitative meta-analytic, and mixed methods research in psychology: The APA Publications and Communications Board task force report. *Am Psychol*. 2018;73(1):26-46.
72. Haddaway NR, Macura B, Whaley P, Pullin AS. ROSES RepOrting standards for Systematic Evidence Syntheses: pro forma, flow-diagram and descriptive summary of the plan and

- conduct of environmental systematic reviews and systematic maps. *Environmental Evidence*. 2018;7:7.
73. Johnson BT, Hennessy EA. Systematic reviews and meta-analyses in the health sciences: Best practice methods for research syntheses. *Soc Sci Med*. 2019;233:237-51.
  74. Blanco D, Altman D, Moher D, Boutron I, Kirkham JJ, Cobo E. Scoping review on interventions to improve adherence to reporting guidelines in health research. *BMJ Open*. 2019;9(5):e026589.